{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:27:35Z","timestamp":1784248055272,"version":"3.55.0"},"reference-count":80,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Small molecule therapies that restore function to the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein, referred to as CFTR modulators, have emerged as a key therapeutic approach for people with CF who carry responsive genetic variants. Their effects have been transformative to the lives of many of those living with CF. As the reach of CFTR modulators expands, new questions arise about their role beyond approved clinical indications for people with CF. One such area of growing interest is the use of CFTR modulator therapy during pregnancy to treat suspected meconium ileus, a particularly severe fetal and immediate postnatal manifestation of CF. In this review, we summarize the current data about use of CFTR modulator therapy during pregnancy, including reported effects in pregnant persons and their offspring. We describe the potential of this in utero therapy to prevent meconium ileus and to maintain exocrine pancreatic function in infants with CF. However, these potential benefits must be weighed carefully with the known and potential risks of CFTR modulator therapy. We address ethical implications and important knowledge gaps related to prenatal CFTR modulator use during pregnancy. Further evidence is needed to determine best practices for CFTR modulator use during pregnancy.<\/jats:p>","DOI":"10.1542\/neo.27-3-103","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:04:00Z","timestamp":1772323440000},"page":"e157-e169","source":"Crossref","is-referenced-by-count":2,"title":["In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis"],"prefix":"10.1542","volume":"27","author":[{"given":"Angela","family":"Metcalf","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana E.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Martiniano","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Zaretsky","sequence":"additional","affiliation":[{"name":"2Department of Obstetrics, Gynecology and Medicine, Colorado Fetal Care Center, Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith T.","family":"Zemanick","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Sagel","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children\u2019s Hospital Colorado, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"issue":"3","key":"2026022819035440200_r1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros."},{"issue":"10290","key":"2026022819035440200_r2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet."},{"issue":"1","key":"2026022819035440200_r3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers."},{"issue":"18","key":"2026022819035440200_r4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med."},{"issue":"S3","key":"2026022819035440200_r5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.24157","article-title":"Rapid therapeutic advances in CFTR modulator science","volume":"53","author":"Clancy","year":"2018","journal-title":"Pediatr Pulmonol."},{"issue":"46","key":"2026022819035440200_r6","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"44","key":"2026022819035440200_r7","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2026022819035440200_r8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcf.2024.07.015","article-title":"Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor\/tezacaftor\/ivacaftor","volume":"24","author":"Sanders","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"19","key":"2026022819035440200_r9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med."},{"issue":"10212","key":"2026022819035440200_r10","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet."},{"issue":"12","key":"2026022819035440200_r11","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11\u00a0years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"2026022819035440200_r12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135\u00a0years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"key":"2026022819035440200_r13","volume-title":"Patient Registry Annual Data Report 2023","author":"Cystic Fibrosis Foundation Patient Registry","year":"2024"},{"issue":"2","key":"2026022819035440200_r14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/d41573-025-00008-y","article-title":"FDA approves next-generation triple therapy for cystic fibrosis","volume":"24","author":"Mullard A","year":"2025","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"2026022819035440200_r15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12\u00a0years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med."},{"issue":"3","key":"2026022819035440200_r16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11\u00a0years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir Med."},{"issue":"5","key":"2026022819035440200_r17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to &lt;12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"issue":"2","key":"2026022819035440200_r18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest."},{"issue":"4","key":"2026022819035440200_r19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O\u2019Connor","year":"2021","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r21","author":"Annual Report ECFSPR 2023"},{"issue":"1","key":"2026022819035440200_r22","first-page":"47","article-title":"Pregnancy in people with cystic fibrosis treated with highly effective modulator therapy","volume":"145","author":"Goralski","year":"2025","journal-title":"Obstet Gynecol."},{"issue":"3","key":"2026022819035440200_r23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"1","key":"2026022819035440200_r24","doi-asserted-by":"crossref","first-page":"98.e1","DOI":"10.1016\/j.ajog.2014.07.018","article-title":"Medical and obstetric complications among pregnant women with cystic fibrosis","volume":"212","author":"Patel","year":"2015","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"2026022819035440200_r25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r26","doi-asserted-by":"crossref","first-page":"116155","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother."},{"key":"2026022819035440200_r27","volume-title":"Package Insert","author":"Trikafta (elexacaftor\/tezacaftor\/ivacaftor)","year":"2021"},{"issue":"4","key":"2026022819035440200_r28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r30","doi-asserted-by":"crossref","first-page":"1274303","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"2026022819035440200_r31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","article-title":"CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study","volume":"24","author":"Chouchana","year":"2025","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r32","volume-title":"Package insert","author":"Kayldeco (Ivacaftor)","year":"2025"},{"issue":"1","key":"2026022819035440200_r33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","article-title":"CF Ferrets exposed to in utero ivacaftor do not develop lens abnormalities","volume":"24","author":"Taylor-Cousar","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"6","key":"2026022819035440200_r34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcf.2024.03.012","article-title":"Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis","volume":"23","author":"McNally","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"2","key":"2026022819035440200_r38","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r39","first-page":"101553","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep."},{"issue":"1","key":"2026022819035440200_r40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcf.2024.09.025","article-title":"Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports","volume":"24","author":"Kolaczkowski","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"4","key":"2026022819035440200_r41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest."},{"issue":"12","key":"2026022819035440200_r42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J Histochem Cytochem."},{"issue":"suppl 2","key":"2026022819035440200_r43","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2017.06.007","article-title":"Meconium ileus in cystic fibrosis","volume":"16","author":"Sathe","year":"2017","journal-title":"J Cyst Fibros."},{"issue":"5","key":"2026022819035440200_r44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/MPG.0b013e3181bb3427","article-title":"Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis","volume":"50","author":"Gorter","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"7","key":"2026022819035440200_r45","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/jcu.23528","article-title":"Hyperechogenic fetal bowel: current evidence-based prenatal diagnosis and management","volume":"51","author":"Vena","year":"2023","journal-title":"J Clin Ultrasound."},{"issue":"4","key":"2026022819035440200_r46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pd.5638","article-title":"Outcome of fetal echogenic bowel: a systematic review and meta-analysis","volume":"41","author":"D\u2019Amico","year":"2021","journal-title":"Prenat Diagn."},{"issue":"4","key":"2026022819035440200_r47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pcl.2016.04.004","article-title":"Cystic fibrosis diagnosis and newborn screening","volume":"63","author":"Rosenfeld","year":"2016","journal-title":"Pediatr Clin North Am."},{"issue":"1","key":"2026022819035440200_r48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1373\/clinchem.2019.305011","article-title":"Noninvasive prenatal diagnosis for cystic fibrosis: implementation, uptake, outcome, and implications","volume":"66","author":"Chandler","year":"2020","journal-title":"Clin Chem."},{"issue":"6","key":"2026022819035440200_r49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jcf.2025.08.004","article-title":"Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy","volume":"24","author":"Wynn","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"1","key":"2026022819035440200_r50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1542\/peds.105.1.53","article-title":"Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening","volume":"105","author":"Lai","year":"2000","journal-title":"Pediatrics."},{"issue":"5","key":"2026022819035440200_r51","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1183\/13993003\/erj.18.5.784","article-title":"The impact of meconium ileus on the clinical course of children with cystic fibrosis","volume":"18","author":"Evans","year":"2001","journal-title":"Eur Respir J."},{"issue":"4","key":"2026022819035440200_r52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.20092","article-title":"Longitudinal pulmonary status of cystic fibrosis children with meconium ileus","volume":"38","author":"Li","year":"2004","journal-title":"Pediatr Pulmonol."},{"issue":"6","key":"2026022819035440200_r53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00431-017-2906-z","article-title":"Body composition and lung function in children with cystic fibrosis and meconium ileus","volume":"176","author":"Doulgeraki","year":"2017","journal-title":"Eur J Pediatr."},{"issue":"6","key":"2026022819035440200_r54","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jcf.2019.09.008","article-title":"Differences in clinical outcomes of paediatric cystic fibrosis patients with and without meconium ileus","volume":"18","author":"Tan","year":"2019","journal-title":"J Cyst Fibros."},{"issue":"485","key":"2026022819035440200_r55","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med."},{"issue":"5","key":"2026022819035440200_r56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros."},{"issue":"2","key":"2026022819035440200_r57","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther."},{"issue":"7","key":"2026022819035440200_r58","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med."},{"issue":"3","key":"2026022819035440200_r59","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros."},{"key":"2026022819035440200_r60","first-page":"S1569","article-title":"Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor\/tezacaftor\/ivacaftor","author":"Haskett","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibros."},{"issue":"3","key":"2026022819035440200_r62","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.3705","article-title":"Predicting maternal and fetal exposures of elexacaftor-tezacaftor-ivacaftor during pregnancy through physiologically based pharmacokinetic models","volume":"118","author":"Hong","year":"2025","journal-title":"Clin Pharmacol Ther."},{"issue":"2","key":"2026022819035440200_r63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcf.2015.01.006","article-title":"Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation","volume":"14","author":"Bodewes","year":"2015","journal-title":"J Cyst Fibros."},{"issue":"7","key":"2026022819035440200_r64","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet."},{"issue":"1","key":"2026022819035440200_r65","doi-asserted-by":"crossref","first-page":"e27463","DOI":"10.1002\/ppul.27463","article-title":"Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr Pulmonol."},{"issue":"3","key":"2026022819035440200_r66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2023.10.012","article-title":"Factors associated with pubertal growth outcomes in cystic fibrosis: early growth and puberty in CF","volume":"23","author":"Patil","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"5","key":"2026022819035440200_r67","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1099800416643585","article-title":"Growth deficiency in cystic fibrosis is observable at birth and predictive of early pulmonary function","volume":"18","author":"Darrah","year":"2016","journal-title":"Biol Res Nurs."},{"issue":"1","key":"2026022819035440200_r68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/andr.12450","article-title":"Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling","volume":"6","author":"de Souza","year":"2018","journal-title":"Andrology."},{"issue":"4","key":"2026022819035440200_r69","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(01)64278-2","article-title":"Normal vas deferens in fetuses with cystic fibrosis","volume":"158","author":"Gaillard","year":"1997","journal-title":"J Urol."},{"issue":"5","key":"2026022819035440200_r70","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros."},{"issue":"10","key":"2026022819035440200_r71","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2\u00a0years of age with cystic fibrosis homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"2026022819035440200_r72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000475929","article-title":"Fetal Treatment 2017: the evolution of fetal therapy centers - a joint opinion from the International Fetal Medicine and Surgical Society (IFMSS) and the North American Fetal Therapy Network (NAFTNet)","volume":"42","author":"Moon-Grady","year":"2017","journal-title":"Fetal Diagn Ther."},{"issue":"8","key":"2026022819035440200_r73","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/pd.6163","article-title":"A new ethical framework to determine acceptable risks in fetal therapy trials","volume":"42","author":"Hendriks","year":"2022","journal-title":"Prenat Diagn."},{"issue":"11","key":"2026022819035440200_r74","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1014379","article-title":"A randomized trial of prenatal versus postnatal repair of myelomeningocele","volume":"364","author":"Adzick","year":"2011","journal-title":"N Engl J Med."},{"issue":"19","key":"2026022819035440200_r75","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMc1800352","article-title":"Maternal sirolimus therapy for fetal cardiac rhabdomyomas","volume":"378","author":"Barnes","year":"2018","journal-title":"N Engl J Med."},{"issue":"11","key":"2026022819035440200_r76","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for prenatal therapy of spinal muscular atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N Engl J Med."},{"issue":"1","key":"2026022819035440200_r77","doi-asserted-by":"crossref","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res."},{"key":"2026022819035440200_r78","article-title":"The mothers who aren\u2019t waiting to give their children cystic-fibrosis drugs","volume-title":"The Atlantic.","author":"Zhang","year":"2024"},{"issue":"5","key":"2026022819035440200_r79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"2026022819035440200_r80","doi-asserted-by":"crossref","unstructured":"Szentpetery\n              S\n            , RivaD, BlumenfeldYJ, . PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report. J Cyst Fibros.2025;24(6):1058\u20131066. PubMed doi: 10.1016\/j.jcf.2025.07.015","DOI":"10.1016\/j.jcf.2025.07.015"}],"container-title":["NeoReviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/27\/3\/e157\/1915880\/neoreviews.092025cmerev00152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/neoreviews\/article-pdf\/27\/3\/e157\/1915880\/neoreviews.092025cmerev00152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:04:13Z","timestamp":1772323453000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/neoreviews\/article\/27\/3\/e157\/206743\/In-Utero-CFTR-Modulator-Therapy-in-Fetuses-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/neo.27-3-103","relation":{},"ISSN":["1526-9906"],"issn-type":[{"value":"1526-9906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}